Article Text

Download PDFPDF
Continuing paroxetine treatment reduces recurrence of major depression in the elderly

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

OpenUrlCrossRefPubMedWeb of Science

Q Do paroxetine and psychotherapy reduce recurrent episodes of depression in the elderly?


Embedded ImageDesign:

Two by two randomised controlled trial (randomisation stratified by number of episodes, use of additional pharmacotherapy, and degree of cognitive impairment).

Embedded ImageAllocation:


Embedded ImageBlinding:

Double blinded (for drug treatment).

Embedded ImageFollow up period:

Two years.

Embedded ImageSetting:

A university based clinic, Pittsburgh, USA; 1999 to 2005.

Embedded ImagePatients:

116 people (⩾70 years old) who achieved a recovery from major depression (DSM-IV and a score of ⩾15 on the Hamilton Rating Scale for Depression and ⩾17 on the Folstein Mini-Mental State Examination) with open label paroxetine (10 mg daily initially, titrated up to 40 mg daily if necessary) and psychotherapy. A recovery was defined as a Hamilton score of 0 to 10 for three consecutive weeks, …

View Full Text


  • For correspondence: Charles F Reynolds III, Western Psychiatric Institute and Clinic, 3811 O’Hara Street, Room E-1135, Pittsburgh, PA 15213, USA; reynoldscf{at}

  • Sources of funding: National Institute of Mental Health, the National Center for Minority Health and Health Disparities, GlaxoSmithKline.